In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Paxlovid, which combines a new Pfizer pill with the old antiviral ritonavir, is currently authorized for use in the first days of a COVID infection to prevent severe disease in high-risk patients.

Pfizer’s flagship Covid drug can have dangerous interactions with common medications, a review has found. Paxlovid gained emergency use authorization in the US in December last year as an ...

Stock Markets Published09/07/2022, 09:04 AM Updated09/07/2022, 12:26 PM Pfizer donates Paxlovid to group targeting COVID in poorer countries View all comments (0)0 PFE 0.47% By Jennifer Rigby ...

Bourla said Pfizer had supplied only a few thousand courses of Paxlovid to China during 2022. That rose to millions of courses during December and the first week of January, he added.

Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported ...

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19 and PAXLOVID (including qualitative assessments of available data, potential benefits, expectations ...

Paxlovid, Pfizer's highly effective antiviral COVID-19 drug, has begun Phase 2 and 3 trials for children between the ages of six and 17 years old, the company announced.

With authorisation, Pfizer’s oral antiviral candidate Paxlovid is an investigational SARS-CoV-2 protease inhibitor could be prescribed at the first sign of COVID-19 infection. Pfizer has announced an ...